Sotatercept; Placebo
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00931606/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование прекращено досрочно, новых участников не набирают.
- Возраст участников: от 18 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 30 чел. во всех странах исследования.
- Плановая дата окончания (11.2010) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Опухольнужен измеримый очаг (RECIST)
- Стадияметастатическая (IV)
- Ожидаемая продолжительность жизнине меньше 6 мес.
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 19
Критерии включения
- Has a histologically confirmed diagnosis of breast cancer documented by cytology or biopsy.
- Has evidence of metastatic breast cancer with a minimum of one lesion per Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v 1.1) criteria.
- Is receiving a chemotherapy regimen including one of the following: anthracycline, taxane, gemcitabine, vinorelbine or capecitabine.
- Has planned treatment with the same chemotherapy regimen for a minimum of 9 weeks after Day 1 of study intervention administration.
- ≥ 30 days elapsed (from Day 1) since previous treatment with an erythropoiesis stimulating agent (ESA) (including treatment with intravenous (IV) iron) for chemotherapy induced anemia.
- ≥ 7 days elapsed (from Day 1) since the last red blood cell (RBC) transfusion and receipt of ≤ 2 units of blood in the past 30 days.
- Life expectancy of ≥ 6 months.
Критерии невключения
- Has had prior radiation therapy to > 20% of the whole skeleton.
- Has had > 5 prior chemotherapy treatment regimens for metastatic breast cancer.
- Has a history of autoimmune or hereditary hemolysis or gastrointestinal bleeding.
- Has clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or genitourinary disease unrelated to underlying hematologic disorder.
- Has heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher.
- Has a recent history of thrombosis, deep vein thrombosis (DVT), pulmonary emboli, or embolic stroke, occurring within the last 6 months.
- Has untreated central nervous system (CNS) metastases or CNS metastases treated with whole brain radiotherapy < 6 months prior to Day 1.
- Has a diagnosis of a myeloid malignancy or known history of myelodysplasia.
- Has a history of second malignancy within 5 years (except excised and cured basal cell carcinoma, squamous cell carcinoma of the skin or cervical carcinoma in situ).
- Has had administration of IV antibiotics or febrile (temperature elevation > 38 ° C) within 14 days of Day 1.
- Has uncontrolled hypertension.
- Has known history of hepatitis B surface antigen (HBsAg and HB core antibody (Ab)), human immunodeficiency virus (HIV) antibody or active hepatitis C.
- Has clinically significant iron (transferrin saturation < 20%), vitamin B12, or folate deficiency.
- Has a history of anemia as a result of inherited hemoglobinopathy such as sickle cell anemia or thalassemia.
- Has a history of autoimmune or hereditary hemolysis; active gastrointestinal bleeding (within the last 6 months as compared to Day 1).
- Has received treatment with another investigational drug or device within 1 month prior to Day 1.
- Is pregnant or lactating.
- Has a history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product.
- Has had major surgery within 30 days prior to Day 1 (patients must have completely recovered from any previous surgery prior to Day 1).
Источник: ClinicalTrials.gov, NCT00931606 · запись обновлена в реестре 13 сентября 2023.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 21
- Percentage of Participants Who Achieved a Hematopoietic Response — Baseline and Up to ~145 Days
Цель исследования
The purpose of this study is to evaluate the percentage of participants in each sotatercept dose regimen who achieve a hematopoietic response during the treatment period including up to 2 months after the last dose of sotatercept treatment of chemotherapy-induced anemia (CIA) in participants with metastatic breast cancer. Hematopoietic response was defined as an increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of sotatercept in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA).
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00931606 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.